Literature DB >> 3085230

Guidelines for the clinical and economic evaluation of health care technologies.

G Guyatt, M Drummond, D Feeny, P Tugwell, G Stoddart, R B Haynes, K Bennett, R Labelle.   

Abstract

The health care system is routinely confronted with promising new technologies. In the past, most new technologies have been integrated into clinical practice without a rigorous demonstration of their effectiveness or efficiency. In order to provide a more rational approach to the adoption and utilization of health technology a comprehensive set of guidelines for both clinical and economic evaluation is proposed. While conceived of as an ideal that is unlikely to be universally met in practice, it is argued that decision making can be improved by striving towards this goal. The clinical guidelines stress the advantages of subjecting major new technologies to randomized controlled trials and insisting upon a demonstration of patient benefit in the application of diagnostic technologies. The economic guidelines stress comparisons with relevant alternative uses of the resources and the assessment of the impact on the quality of life. While application of the guidelines will produce rigorous and useful evidence, the final decisions concerning the allocation of health care resources must rest fundamentally on social value judgements and not solely, or even primarily, on informed expert opinion.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  1986        PMID: 3085230     DOI: 10.1016/0277-9536(86)90046-8

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  21 in total

Review 1.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

2.  Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Authors:  M Iskedjian; K Trakas; C A Bradley; A Addis; K Lanctôt; D Kruk; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

3.  Principles of pharmacoeconomic analysis of drug therapy.

Authors:  D A Freund; R S Dittus
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 4.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

5.  Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.

Authors:  K E Agro; C A Bradley; N Mittmann; M Iskedjian; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

6.  Economic decision making in healthcare. A standard approach to discounting health outcomes.

Authors:  A L Hillman; M S Kim
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

7.  Diagnostic decision making.

Authors:  A Antczak-Bouckoms; J F Tulloch; A J Bouckoms; D Keith; P Lavori
Journal:  Anesth Prog       Date:  1990 Mar-Jun

8.  The assessment of technology in Ontario's critical care system. Technology Subcommittee of the Working Group on Critical Care, Ontario Ministry of Health.

Authors: 
Journal:  CMAJ       Date:  1991-06-15       Impact factor: 8.262

Review 9.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Diagnostic accuracy of antimyosin scintigraphy in suspected myocarditis.

Authors:  J Narula; B A Khaw; G W Dec; I F Palacios; J B Newell; J F Southern; J T Fallon; H W Strauss; E Haber; T Yasuda
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.